悦康药业(688658.SH)子公司YKYY013注射液获得FDA临床试验批准

智通财经2025-09-22

智通财经APP讯，悦康药业(688658.SH)发布公告，公司子公司北京悦康科创医药科技股份有限公司(简称“悦康科创”)于近日获得美国食品药品监督管理局(以下简称“FDA”)关于同意 YKYY013 注射液用于治疗慢性乙型肝炎病毒感染进行临床试验的函告(Study May Proceed Letter，IND 编号：177486)。YKYY013 注射液是悦康科创和公司全资子公司杭州天龙药业...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2569200977?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-22 17:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569200977","market":"fut","top_or_hot":-1,"title":"悦康药业(688658.SH)子公司YKYY013注射液获得FDA临床试验批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，悦康药业(688658.SH)发布公告，公司子公司北京悦康科创医药科技股份有限公司(简称“悦康科创”)于近日获得美国食品药品监督管理局(以下简称“FDA”)关于同意 YKYY013 注射液用于治疗慢性乙型肝炎病毒感染进行临床试验的函告(Study May Proceed Letter，IND 编号：177486)。YKYY013 注射液是悦康科创和公司全资子公司杭州天龙药业...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1347948.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>悦康药业(688658.SH)子公司YKYY013注射液获得FDA临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n悦康药业(688658.SH)子公司YKYY013注射液获得FDA临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-22 17:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1347948.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，悦康药业(688658.SH)发布公告，公司子公司北京悦康科创医药科技股份有限公司(简称“悦康科创”)于近日获得美国食品药品监督管理局(以下简称“FDA”)关于同意 YKYY013 注射液用于治疗慢性乙型肝炎病毒感染进行临床试验的函告(Study May Proceed Letter，IND 编号：177486)。YKYY013 注射液是悦康科创和公司全资子公司杭州天龙药业...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1347948.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688658","symbol_name":"悦康药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1347948.html","article_id":"2569200977","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569200977","pubTimestamp":1758532650,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，悦康药业 发布公告，公司子公司北京悦康科创医药科技股份有限公司于近日获得美国食品药品监督管理局关于同意 YKYY013 注射液用于治疗慢性乙型肝炎病毒感染进行临床试验的函告。临床拟用于慢性乙型肝炎病毒感染的治疗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688658":"悦康药业","BK0239":"医药制造"},"translate_title":"YKYY013 injection, a subsidiary of Yuekang Pharmaceutical (688658. SH), received FDA clinical trial approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688658":1.5},"content_text":"智通财经APP讯，悦康药业(688658.SH)发布公告，公司子公司北京悦康科创医药科技股份有限公司(简称“悦康科创”)于近日获得美国食品药品监督管理局(以下简称“FDA”)关于同意 YKYY013 注射液用于治疗慢性乙型肝炎病毒感染进行临床试验的函告(Study May Proceed Letter，IND 编号：177486)。YKYY013 注射液是悦康科创和公司全资子公司杭州天龙药业有限公司自主研发的一款偶联 N-乙酰半乳糖胺(N-acetylgalactosamine，GalNAc)配体的化学合成双链 siRNA 药物，通过 RNA 干扰作用有效沉默乙型肝炎病毒(HBV)基因组转录的信使 RNA(Messenger RNA，mRNA)，进而抑制乙肝病原蛋白的产生，抑制 HBV 的复制，并为宿主免疫重建创造条件，最终实现乙肝的功能性治愈。临床拟用于慢性乙型肝炎病毒感染的治疗。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2569200977","isCrawlerRequest":true}